4//SEC Filing
Pontifax Management 4 G.P. (2015) Ltd. 4
Accession 0001144204-19-032482
CIK 0001035354other
Filed
Jun 25, 8:00 PM ET
Accepted
Jun 26, 4:44 PM ET
Size
46.1 KB
Accession
0001144204-19-032482
Insider Transaction Report
Form 4
Pontifax (Cayman) IV L.P.
10% Owner
Transactions
- Purchase
Common Stock
2019-06-24$9.00/sh+46,933$422,397→ 567,329 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+42,261$380,349→ 510,846 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+86,806$781,254→ 1,049,310 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+24,000$216,000→ 24,000 total(indirect: By Pontifax Investment Fund)
Transactions
- Purchase
Common Stock
2019-06-24$9.00/sh+42,261$380,349→ 510,846 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+24,000$216,000→ 24,000 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+86,806$781,254→ 1,049,310 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+46,933$422,397→ 567,329 total(indirect: By Pontifax Investment Fund)
Pontifax (China) IV L.P.
10% Owner
Transactions
- Purchase
Common Stock
2019-06-24$9.00/sh+46,933$422,397→ 567,329 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+24,000$216,000→ 24,000 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+42,261$380,349→ 510,846 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+86,806$781,254→ 1,049,310 total(indirect: By Pontifax Investment Fund)
Pontifax (Israel) IV, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2019-06-24$9.00/sh+42,261$380,349→ 510,846 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+86,806$781,254→ 1,049,310 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+46,933$422,397→ 567,329 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+24,000$216,000→ 24,000 total(indirect: By Pontifax Investment Fund)
Pontifax IV GP L.P.
10% Owner
Transactions
- Purchase
Common Stock
2019-06-24$9.00/sh+42,261$380,349→ 510,846 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+24,000$216,000→ 24,000 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+86,806$781,254→ 1,049,310 total(indirect: By Pontifax Investment Fund) - Purchase
Common Stock
2019-06-24$9.00/sh+46,933$422,397→ 567,329 total(indirect: By Pontifax Investment Fund)
Footnotes (5)
- [F1]Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that closed on June 24, 2019.
- [F2]Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- [F3]Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- [F4]Represents shares of the Issuer held by Pontifax (China) IV L.P. ("China IV"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- [F5]Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.("Late Stage Fund"). Pontifax Late Stage GP Ltd. ("Late Stage GP"), the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Each of Management 4, Pontifax IV, Late Stage Fund and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
Documents
Issuer
Eloxx Pharmaceuticals, Inc.
CIK 0001035354
Entity typeother
IncorporatedIsrael
Related Parties
1- filerCIK 0001726334
Filing Metadata
- Form type
- 4
- Filed
- Jun 25, 8:00 PM ET
- Accepted
- Jun 26, 4:44 PM ET
- Size
- 46.1 KB